

Title: Chemokine Receptor 4 (CCR4) is a Promising Target for Development of New Tumor Immunotherapy



Speaker

Ryuzo Ueda, M.D.,Ph.D.

Professor Emeritus, Senior Adviser, Nagoya City University
Professor, Dept. of Tumor Immunology, Aichi Medical University, Japan



Chairman

Makoto Ogawa, M.D.

Emeritus President, Aichi Cancer Center, Japan

Ryuzo Ueda, M.D.,Ph.D.

EDUCATION:

1969: Nagoya University School of Medicine, M.D.
1969-1976: Clinical Fellow, Nagoya University School of Medicine, Nagoya
1976-1980: Research Fellow, Research Associate (1979), Memorial Sloan-Kettering Cancer Center, N.Y., USA

CURRENT POSITION:

2010- Professor Emeritus, Senior Adviser, Nagoya City University
2012- Professor, Dept. of Tumor Immunology, Aichi Medical University

SPECIALTIES AND FIELD OF INTEREST:

Specialty: Hematology and Medical Oncology
Field of Interest; Molecular Target Therapy for Cancer, Monoclonal Antibody Therapy

RECENT SELECTED ORIGINAL PAPER:

1. Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, Sugiyama D, Ito A, Fukumori Y, Utsunomiya A, Inagaki H, Old LJ, Ueda R, Sakaguchi S. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. *Blood*, 119: 3097-3104 2012.
2. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. *J Clin Onol.*, 30: 837-842, 2012.
3. Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. *J Med Virol.*, 83: 412-418, 2011.
4. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. *Cancer Sci.*, 102:44-50, 2011.
5. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2R γ (null) mouse lymphoma model. Sato F, Ito A, Ishida T, Mori F, Takino H, Inagaki A, Ri M, Kusumoto S, Komatsu H, Iida S, Okada N, Inagaki H, Ueda R. *Cancer Immunol Immunother.* 59: 1791-1800, 2010
6. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R. *J Clin Oncol.* 20: 1591-1598, 2010.
7. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, Shitara K, Ueda R. *Clin Cancer Res.*, 16:1520-1531, 2010.
8. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R γ (null) mice in vivo. *J Immunol.*, 183:4782-4791, 2009.
9. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2R γ (null) mouse model. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. *Cancer Immunol Immunother.*, 58: 1195-1206, 2008.
10. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, Takeuchi G, Shimizu S, Ito M, Komatsu H, Wakita A, Eimoto T, Matsushima K and Ueda R. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. *Clinical Cancer Res.*, 9:3625-3634, 2003.

IAAO2012 Title of the Talk:

Chemokine Receptor 4 (CCR4) is a Promising Target for Development of New Tumor Immunotherapy